Investment

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

The commercialisation firm remains content with its position despite revenues drying up following its big exit from Virginia Tech's HawkEye 360 last year.

The OSU spinout plans to scale up the distribution of its robotics system, which has human-like legs to navigate complex environments.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Five years after being co-founded by UCL researchers, Ori Biotech has brought its overall funding to $41m.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

With hundreds of university venture funds, internal commercialisation vehicles and third-party firms the reality in today’s innovation ecosystem, selecting the nominees and the winner for Investment Unit of the Year is increasingly challenging.

Goldwind, Legal & General and Equinor have all taken part in a series D that achieved a $41m first close and boosted the Oxford spinout’s total equity and debt to more than $118m.

Ribon Therapeutics has emerged out of stealth after three years of developing a lead asset targeting cancer based on research at MIT, UT Southwestern and Harvard Medical School.

Ambys Medicines has raised $60m in a series A round backed by Takeda and signed a strategic partnership agreement with the corporate worth $80m.